San Diego-based eFFECTOR Therapeutics has raised $45 million in Series A venture capital to develop small molecules that selectively regulate protein synthesis – otherwise known as translation – and advance a cancer drug candidate into human trials within three years.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?